Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 11Neoplasm Metastasis 8Prostatic Neoplasms 6Triple Negative Breast Neoplasms 5Multiple Myeloma 5Lymphoma, Mantle-Cell 5Lymphoma 5Lung Neoplasms 5Leukemia, Myeloid, Acute 4Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Biphenotypic, Acute 3Hematologic Neoplasms 3Fallopian Tube Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Liposarcoma 2Glioma 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2

Interventions

Cyclophosphamide 2sargramostim 1iberdomide 1fludarabine 1dinutuximab 1Topotecan 1Magnetic Resonance Spectroscopy 1Influenza Vaccines 1Colony-Stimulating Factors 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Ganglioneuroblastoma × Biopsy × Clear all
NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡